title: Prognostic role of hepatoma-derived growth factor in solid tumors of Eastern Asia: a systematic review and meta- analysis.
abstract: Hepatoma-derived growth factor (HDGF) is a novel jack-of-all-trades in cancer. Here we quantify the prognostic impact of this biomarker and assess how consistent is its expression in solid tumors. A comprehensive search strategy was used to search relevant literature updated on October 3, 2014 in PubMed, EMBASE and WEB of Science. Correlations between HDGF expression and clinicopathological features or cancer prognosis was analyzed. All pooled HRs or ORs were derived from random-effects models. Twenty-six studies, primarily in Eastern Asia, covering 2,803 patients were included in the analysis, all of them published during the past decade. We found that HDGF overexpression was significantly associated with overall survival (OS) (HROS=2.35, 95%CI=2.04-2.71, p<0.001) and disease free survival (DFS) (HRDFS=2.25, 95%CI =1.81-2.79, p<0.001) in solid tumors, especially in non-small cell lung cancer, hepatocellular carcinoma and cholangiocarcinoma (CCA). Moreover, multivariate survival analysis showed that HDGF overexpression was an independent predictor of poor prognosis (HROS=2.41, 95%CI: 2.02-2.81, p<0.001; HRDFS=2.39, 95%CI: 1.77-3.24, p<0.001). In addition, HDGF overexpression was significantly associated with tumor category (T3-4 versus T1-2, OR=2.12, 95%CI: 1.17-3.83, p=0.013) and lymph node status (N+ versus N-, OR=2.37, 95%CI: 1.31-4.29, p=0.03) in CCA. This study provides a comprehensive examination of the literature available on the association of HDGF overexpression with OS, DFS and some clinicopathological features in solid tumors. Meta-analysis results provide evidence that HDGF may be a new indicator of poor cancer prognosis. Considering the limitations of the eligible studies, other large-scale prospective trials must be conducted to clarify the prognostic value of HDGF in predicting cancer survival.
authors.affiliation: Department of Radiation Oncology, Qilu Hospital of Shandong University, Shandong University, Jinan, China E-mail : qlcyf2014new@163.com.
authors.forename: Ci-Hang
authors.initials: CH
authors.lastname: Bao
authors.forename: Kun
authors.initials: K
authors.lastname: Liu
authors.forename: Xin-Tong
authors.initials: XT
authors.lastname: Wang
authors.forename: Wei
authors.initials: W
authors.lastname: Ma
authors.forename: Jian-Bo
authors.initials: JB
authors.lastname: Wang
authors.forename: Cong
authors.initials: C
authors.lastname: Wang
authors.forename: Yi-Bin
authors.initials: YB
authors.lastname: Jia
authors.forename: Na-Na
authors.initials: NN
authors.lastname: Wang
authors.forename: Bing-Xu
authors.initials: BX
authors.lastname: Tan
authors.forename: Qing-Xu
authors.initials: QX
authors.lastname: Song
authors.forename: Yu-Feng
authors.initials: YF
authors.lastname: Cheng
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000096:biosynthesis*; D018572:Disease-Free Survival; D005202:Asia, Eastern; D005260:Female; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000096:biosynthesis*; D008207:Lymphatic Metastasis / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000401:mortality* / Q000473:pathology*; D011379:Prognosis; D018570:Risk Assessment
chemical_list: D014408:Biomarkers, Tumor; D036341:Intercellular Signaling Peptides and Proteins; C051610:hepatoma-derived growth factor